Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

CUSIP: 98422T100

Q4 2024 13F Holders as of 31 Dec 2024

Security type / class
Equity / Common Stock, par value $0.0001 per share
Total 13F shares
25,814,355
Total 13F value
$24,660,128
Holder snapshot 6 signals
Share change
-173,993
SEC-reported price per share
$0.96
Number of holders
34
Value change
-$144,644
Number of buys
10
Number of sells
11
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
6,426,426

Security key

98422T100

Report period

Q4 2024

Institutions

34

Top holders

10

XLO full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Xilio Therapeutics, Inc. SEC filings Xilio Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
30 Sep 2024
13F 3/4/5 Lead comparable stake: 71% Showing 1-6 of 15 holder rows.

Quick read

Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 71%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Bain Capital Life Sciences Investors, LLC's linked filing trail.
Comparable ownership Top 5
Bain Capital Life Sciences Invest... 71%
Rock Springs Capital Management LP 47%
MORGAN STANLEY 24%
TAKEDA PHARMACEUTICAL CO LTD 23%
RiverVest Venture Management LLC 22%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Bain Capital Life Sciences Investors, LLC
13F 3/4/5
Company · 10%+ Owner
13F 3/4/5
71%
$3,597,282
4,566,817 shares
 — 30 Sep 2024
Rock Springs Capital Management LP
13F 3/4/5
Company · 10%+ Owner
13F 3/4/5
47%
$2,365,667
3,003,259 shares
 — 30 Sep 2024
MORGAN STANLEY
13F
Company
13F
24%
$1,198,960
1,522,102 shares
 — 30 Sep 2024
TAKEDA PHARMACEUTICAL CO LTD
3/4/5 13F
10%+ Owner · Company
3/4/5 13F
23%
from 13F
$1,224,350
1,475,121 shares
 — 26 Oct 2021
RiverVest Venture Management LLC
13F
Company
13F
22%
$1,135,425
1,441,444 shares
 — 30 Sep 2024
FMR LLC
3/4/5 13F
Other* · Company
3/4/5 13F
22%
from 13F
$1,583,366
1,907,670 shares
 — 26 Oct 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
34
Shares
25,814,355
Rows available
34
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2024 vs Q4 2025 Across Filers

Q4 2025 holders
37
Q4 2024 holders
34
Holder diff
-3
Investor Q4 2025 Shares Q4 2024 Shares Share Diff Share Chg % Q4 2025 value Q4 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .